Adaptive Biotechnologies Corporation ADPT
As ofNov 20, 2026, 1:24 PM EST
- YTD
- +71.80%
- 1 year
- +70.96%
5D -1.00 (-3.44%)
- Market cap
- 4.52B
- Revenue (ttm)
- 298.01M
- Profit margin
- -23.66%
- EPS (ttm)
- -0.45
- Shares out
- 161.88M
- Forward P/E
- -841.58
- YTD return
- +71.80%
- 1-year return
- +70.96%
- 50-day average
- 27.14
- 200-day average
- 20.23
- Volume
- 639.83K
- Avg volume
- 2.19M
- Open
- 27.43
- Previous close
- 28.05
- Day's range
- 27.15 – 28.23
- 52-week range
- 12.00 – 32.21
- Beta
- 2.15
- Analysts
- Strong Buy
- Price target
- 32.57 (+16.7%)
- Earnings date
- Feb 4, 2027
Key statistics
- Enterprise value
- 4.72B
- Price / sales
- 15.24
- Price / book
- 25.71
- Revenue growth
- -10.70%
- Free cash flow
- 14.43M
- Total cash
- 298.95M
- Total debt
- 408.97M
- Return on equity
- -36.45%
- Short % of float
- 8.93%
Fundamental scorecard
5 of 25 checks passed on ADPT’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 21.00
- Target (mean)
- 32.57
- Target (high)
- 35.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate -0.04034.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | -0.04 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.09108 | 0.02 | +0.11 | +121.96% |
| Jul 28, 2026 | Jun 30, 2026 | -0.13361 | -0.25 | -0.12 | -87.11% |
| May 5, 2026 | Mar 31, 2026 | -0.16 | -0.13 | +0.03 | +18.75% |
| Feb 5, 2026 | Dec 31, 2025 | -0.19 | -0.09 | +0.10 | +52.63% |
| Nov 6, 2025 | Sep 30, 2025 | -0.18 | 0.06 | +0.24 | +133.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Guggenheim | main | Buy | Buy |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 13, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Goldman Sachs | init | — | Buy |
| Sep 22, 2026 | BTIG | main | Buy | Buy |
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- adaptivebiotech.com
News
Adaptive Biotechnologies Highlights clonoSEQ's Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026 Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34
Adaptive Biotechnologies Q3 2026 Earnings Call Transcript
MercadoLibre, Banco Bradesco, Itaú Unibanco And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Your note
Sign in to keep a note on ADPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENZENO SHARON | Officer | Conversion of Exercise of derivative security | Jun 28, 2026 | 221,278 |
| BOBULSKY SUSAN | Officer | Sale | Oct 5, 2026 | 389,350 |
| LO FRANCIS | Officer | Conversion of Exercise of derivative security | Sep 30, 2026 | 223,367 |
| NEUPERT PETER M | Director | Conversion of Exercise of derivative security | Aug 16, 2026 | 130,625 |
| OWEN KATEY EINTERZ | Director | Stock Gift | Aug 30, 2026 | 66,100 |
| PELLINI MICHAEL J | Director | Stock Award(Grant) | Mar 3, 2025 | 69,690 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Viking Global Investors, L.P. | 18.53% | 29,993,708 | 841.32M | Sep 29, 2026 |
| Blackrock Inc. | 9.45% | 15,302,445 | 429.23M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.98% | 6,436,045 | 180.53M | Sep 29, 2026 |
| Shaw D.E. & Co., Inc. | 3.94% | 6,373,294 | 178.77M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 3.52% | 5,702,859 | 159.97M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 3.24% | 5,239,185 | 146.96M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 4,834,309 | 135.60M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.55% | 4,122,023 | 115.62M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.17% | 1,891,303 | 53.05M | Oct 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.08% | 1,742,854 | 48.89M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.04% | 1,687,241 | 47.33M | Aug 30, 2026 |
| ALGER FUNDS-Alger Small Cap Focus Fund | 0.92% | 1,494,214 | 41.91M | Jul 30, 2026 |
